Emerging approaches in hepatocellular carcinoma

Journal of Clinical Gastroenterology

Volumn 41, Issue 9, 2007, Pages 839-854

  Kulik, Laura M ^a   Mulcahy, Mary F ^a   Omary, Reed A ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Orthotopic liver transplantation; Therapy

Indexed keywords

ALBUMIN TC 99M; BORTEZOMIB; CYCLOSPORIN A; DOXORUBICIN; RAPAMYCIN; SORAFENIB; YTTRIUM 90;

ARTIFICIAL EMBOLISM; BEAM THERAPY; CANCER PATIENT; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; ESOPHAGUS VARICES; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MONOTHERAPY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOTOPIC TRANSPLANTATION; PATIENT CARE; PATIENT SELECTION; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; REVIEW; SKIN MANIFESTATION; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; YTTRIUM RADIOISOTOPES;

EID: 34548854252     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318060ac52     Document Type: Review

References (176)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
2. Davilla JA, Morgan RO, Shalib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population based-study. Gastroenterology. 2004;127:1372-1380.
3. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303-1310.
4. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723-731. Epub January 24, 2006.
5. Lopez PM, Villanueva A, Llovet JM. Systemic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547.
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
7. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Sem Liver Dis. 2005;25:212-225.
8. Llovett JM, Fuster J, Briux J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
9. Chen MF, Hwang TL, Jeng LB, et al. Hepatic resection in 120 patients with hepatocellular carcinoma. Ann Surg. 1989;124:1025-1028.
10. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol. 1993;160:1023-1028.
11. Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114-117.
12. Llovet LM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
13. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transplantation. 2003;9:684-692.
14. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systemic review of randomized controlled trials. Ann Oncol. 1997;8:117-136.
15. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532-1538.
16. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transplant Int. 2006;19:288-294.
17. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
18. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630-639.
19. Jessenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002;3:112-121.
20. Zhang HG, Wang J, Yang X, et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004;23:2009-2015.
21. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother. 2006;55:76-84.
22. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluable Apo2 ligand. J Clin Invest. 1999;104:155-162.
23. Walczak H, Miller RE, Ariail K, et al. Tumoricidial activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163.
24. Kim YS, Schwabe RF, Qian T, et al. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology. 2002;36:1498-1508.
25. Ganten TM, Koschny R, Haas TL, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to Trail. Hepatology. 2005;42:588-597.
26. Anan A, Gores GJ. A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome. Hepatology. 2005;42:527-529.
27. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitors PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
28. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
29. Pang R, Poon RTP. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006;242:151-167.
30. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972. Epub December 21, 2004.
31. Abou-Alfa G, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;26:4293-4299.
32. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5:1676-1681.
33. Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54:385-390.
34. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 glass microspheres: preliminary results and clinical follow up. J Nucl Med. 1994;35:1637-1644.
35. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres). Ann Surg. 1965;162:267-278.
36. Humanitarian Device Exemptions (HDE) Regulations: Questions and Answers; Final Guidance for Industry. Available at: http://www.fda.gov/cdrh/ode/guidance/ 1381.html.
37. SIR-Spheres Yttrium-90 microspheres package insert. [Sirtex Medical Web site]. 2004. Available at: http://www.sirtex.com/usa/_datapage/549/SIR- Spheres_User_Manual2.pdf. Accessed November 13, 2006.
38. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994-999.
39. Dancey JE, Shepard FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673-1681.
40. Carr BI. Hepatic arterial 90yttrium glass microspheres (Thereasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplantation. 2004;10:S107-S110.
41. Francois J, Geschwind JF, Salem R, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194-S205.
42. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195-203.
43. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Inter Radiol. 2005;16:1627-1639.
44. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734-1739.
45. Group d'Etude Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 1995;332:1256-1261.
46. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
47. Liu DM, Salem R, Bui J, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005;16:911-935.
48. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses for yttrium-90 microspheres in treating hepatic tumors. Eur J Nucl Med. 1996;23:947-952.
49. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation dose from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298.
50. Murthy R, Kennedy A, Line B, et al. Augmentation of hepatopulmonary shunting following trans-arterial hepatic brachytherapy with Y90 TheraSphere: therapeutic implications. Presented at the Radiological Society of North America, 2002. Chicago, IL.
51. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007. [Epub ahead of print].
52. Rhee TK, Omary RA, Gates V, et al. The effect of catheter-directed CT angiography on Yttrium-90 radioembolization treatment of hepatocelluar carcinoma. J Vasc Interv Radiol. 2005;16:1085-1091.
53. Goin J, Dancey JE, Roberts C, et al. Comparision of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med. 2004;3:49-56.
54. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (Thereasphere®): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522-529.
55. Geschwind J, Ramsey DE, Van der Wal B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol. 2003;26:111-117.
56. Coldwell D, Kennedy A. Treatment of hepatic metastases from breast cancer with Yttrium-90 SIRS-Spheres radioembolization (abstract). Society of Interventional Radiology 2005 Annual Meeting, New Orleans, LA.
57. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
58. Yip D, Allen R, Ashton C, et al. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. Gastroenterol Hepatol. 2004;19:347-349.
59. Lewandowski R, Salem R. Incidence of radiation cholecytitis in patients receiving Y-90 treatment for unresectable liver malignancies. J Vasc Interv Radiol. 2004;15:S162.
60. Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200-208.
61. Ayav A, Habib N, Jiao LR. Portal hypertension secondary to 90Yttrium microspheres: an unknowm complication. J Clin Oncol. 2005;23:8275-8276.
62. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 2: Special topics. J Vasc Interv Radiol. 2006;17:1571-1593.
63. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and safety for tumor recurrence. Liver Transplantation. 2005;11:1117-1126.
64. Okuda K, Ohtsuki T, Artemov D, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928.
65. Nonami T, Yokoyama I, Iwatsuki S, et al. The incidence of portal vein thrombosis at liver transplantation. Hepatology. 1992;16:1195-1198.
66. Gayowski TJ, Martino IR, Echeverri L, et al. A high incidence of naïve portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res. 1996;60:333-338.
67. Davidson BR, Gibson M, Dick R, et al. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation. 1994;57:1174-1177.
68. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2002;95:588-595.
69. Llovet JM, Burroughs A, Bruix J. Hepatocelluar carcinoma. Lancet. 2003;362:1907-1917.
70. Pentecost MJ, Daniels JR, Teitelbaum GP, et al. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interven Radiol. 1993;4:347-351.
71. Lee H-S, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. Cancer. 1997;79:2087-2094.
72. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335-345.
73. Lewandowski R, Alli A, Atassi B, et al. Retraction of portal vein thrombosis following treatment with Y-90 TheraSphere: a secondary sign of tumor response. Society of Interventional Radiology Annual Meeting 2006. Toronto, Canada.
74. Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transplantation. 2006;12:665-673.
75. Mejia GA, Gomez MA, Serrano J, et al. Correlation between the radiographic and histiologic size of hepatocellular carcinoma in patients eligible for liver transplantation. Liver Transplantation. 2006;38:1394-1395.
76. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
77. Lim HK, Han JK. Hepatocellular carcinoma: evaluation of therapeutic response to interventional procedures. Abdom Imaging. 2002;27:168-179.
78. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol. 2000;175:699-704.
79. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiographic-pathologic correlation. Cancer. 2000;88:2452.
80. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
81. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
82. Catalano O, Lobianco R, Esposito M, et al. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: helical CT patterns. Abdom Imaging. 2001;26:375-383.
83. Tsuda M, Majima K, Yamada T. Hepatocellular carcinoma after radiofrequency ablation therapy: dynamic CT evaluation of treatment. Clin Imaging. 2001;25:409-415.
84. Kulik LM, Mulcahy MF, Hunter RD, et al. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transplantation. 2005;11:1127-1131.
85. Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. Am J Roentgenol. 1990;154:763-769.
86. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100.
87. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004;10:7852-7858.
88. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;181:708-710.
89. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505-512.
90. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to Yttrium-90 radioembolization. J Vasc Interv Radiol. 2006;17:1195-2000.
91. Marelli L, Stigliano R, Triantos C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594-606. Epub October 11, 2006.
92. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer. 2001;92:1516-1524.
93. Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197:812-818.
94. Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol. 2005;11:6104-6109.
95. Allgaier HP, Deibert P, Olschewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer. 1998;79:601-605.
96. Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int. 2004;24:625-629.
97. Bloomston M, Binitie O, Fraiji E. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002;68:827-831.
98. Kitamoto M, Imagawa M, Yamada H, et al. Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol. 2003;181:997-1003.
99. Koda M, Ueki M, Maeda Y, et al. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res. 2004;29:18-23.
100. Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to complete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005;25:1189-1196.
101. Chung YL, Jian JJ, Cheng SH, et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006;12:2706-2715.
102. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
103. Marelli L, Stigliano R, Triantos C. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594-606.
104. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15:270-285.
105. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
106. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311-322.
107. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histiopathic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-1086.
108. [UNOS Website]. Available at: http://www.unos.org. Accessed November 13, 2006.
109. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
110. Hsu HC, Wei TC, Tsang YM, et al. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer. 1986;57:1184-1191.
111. Pawalik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplantation. 2005;11:1086-1092.
112. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150-159.
113. Klintmalm GB. Liver transplantation for hepatocellular carcinoma a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479-490.
114. Tamura S, Kato T, Berho M et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136:25-30.
115. Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407-414.
116. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
117. Unitt E, Marshall A, Gelson W, et al. Tumor lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45:246-253.
118. Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? - No, please don't. J Hepatol. 2005;43:563-568.
119. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
120. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transplantation. 2006;12:1260-1267.
121. Yao FY, Ferrell LD, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: the impact of the degree of necrosis from pre-operative loco-regional therapy on recurrence. Gastroenterology. 2005;128:A689.
122. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transplantation. 2005;11:1505-1514.
123. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transplantation. 2004;10:1294-1300.
124. Yao FY. Expanded criteria for hepatocellular carcinoma: downstaging with a view to liver transplantation - yes. Sem Liver Dis. 2006;26:239-247.
125. Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol. 2001;96:1243-1250.
126. Takada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transplantation. 2006;12:912-919.
127. Yeo W, Sung JY, Ward SC, et al. A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. Dig Dis Sci. 1995;40:2516-2521.
128. Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma: a study of 100 untreated cases. Cancer. 1984;54:1461-1465.
129. Lo GH, Lin CY, Lai SC, et al. Endoscopic injection sclerotherapy versus conservative treatment for patients with unresectable hepatocellular carcinoma and bleeding esophageal varices. Gastrointest Endosc. 1991;37:161-164.
130. Cheng CY, Chen GH, Chang CS, et al. Sclerotherapy for esophageal variceal bleeding in advanced hepatocellular carcinoma: an 8-year experience in Twain. J Gastroenterol. 1994;29:474-478.
131. Khuroo MS, Khuroo NS, Farahat KLC, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther. 2005;21:347-361.
132. de Franchis R, on behalf of the Baveno IV Chairpersons and panelists. Evolving consensus in portal hypertension. Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in Portal Hypertension. J Hepatol. 2005;43:167-163.
133. Riantos C, Vlachogiannakos J, Armonis A, et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta blockers: a randomized trial of ligation. Aliment Pharmacol Ther. 2005;21:1435-1443.
134. Jutabha R, Jensen DM, Martin P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology. 2005;128:870-881.
135. De Francgis R. Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding. Hepatology. 2005;43:24-27.
136. Chen CH, Sheu JC, Huang GT, et al. Characteristics of hepatocellular carcinoma presenting with variceal bleeding. J Gastroenterol Hepatol. 1998;13:170-174.
137. Inagaki Y, Unoura M, Kobayashi K. Clinical features and diagnosis of primary liver cancer. In: Tobe T, Kameda H, Okudaira M, et al., eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag; 1992:93-102.
138. Llach J, Teres J, Garcia-Pagan JC, et al. Hipertransaminasemia en el curso de una hemorragia digestiva alta por varices esofagicas en pacientes cirroticos. Su asociacion con el carcinoma hepatocellular. Gastroenterol Hepatol. 1988;11:273-275.
139. Lang BH, Poon RT, Fan ST, et al. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99:2158-2165.
140. Yeh JL, Peng YC, Tung CF, et al. Clinical predictors of large esophagogastric varices in patients with hepatocellular carcinoma. Dig Dis Sci. 2002;47:723-729.
141. Chen WC, Hou MC, Lin HC, et al. Feasibility and potential benefit of maintenance endoscopic variceal ligation in patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: a controlled trial. Gastro Endosc. 2001;54:18-23.
142. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology. 2001;33:1073-1079.
143. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transplantation. 2003;9:557-563.
144. Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795-804.
145. Lo CM, Fan ST, Lui CL, et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transplantation. 2004;10:440-447.
146. Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451-459.
147. Kulik LM, Freise CE, Lok AS, et al. A Comparison of Adult Living Donor (LDLT) to Deceased Donor Liver Transplant (DDLT) for Hepatocellular Carcinoma (HCC): Data From the A2ALL Study. Alexandria, VA: American Association for the Study of Liver Diseases; 2005.
148. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282.
149. Hwang S, Lee SG, Joh JW, et al. Liver transplant for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor transplant. Liver Transplantation. 2005;11:1265-1272.
150. Yokoyama I, Carr B, Sartsu H, et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplant. Cancer. 1991;68:2095-2100.
151. Steininger R, Herbst F, Fugger R, et al. Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma. Transplant Proc. 1992;24:2690-2692.
152. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transplantation. 2005;11:494-496.
153. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation. 2002;74:1746-1751.
154. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397:530-534.
155. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
156. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 2002;73:1565-1572.
157. Schumacher G, Oidtmann M, Rueggeberg A, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11:1420-1425.
158. Andrassy J, Graeb C, Rentsch M, et al. mTOR inhibition and its effect on cancer in transplantation. Transplantation. 2005;80:171-174.
159. Morales JM, Campistol JM, Kreis H, et al. Sirolimus-based Therapy With or Without Cyclosporine: Long Term Follow-up in Renal Transplant Patients. Washington, DC: American Transplant Congress; 2003. Abstract 775.
160. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809.
161. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35:25S.
162. Kauffman HM, Cherikh WS, Cheng Y, et al. News release: patients receiving mTOR inhibitors exhibit fewer early malignancies than those receiving cyclosporine-based regimens: OPTN/UNOS (Organ Procurement and Transplant Network/United Network for Organ Sharing), 2004.
163. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
164. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation. 2004;10:1301-1311.
165. Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transplantation. 2005;11:494-496.
166. Zhou J, Fan J, Wang Z, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol. 2006;12:3114-3118.
167. Wall W. Hepatocellular cancer, transplantation and sirolimus. Liver Transplantation. 2004;10:1312-1314.
168. Elsharkawi M, Staib L, Henne-Bruns D, et al. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005;79:855-857.
169. Stippel DL, Kasper HU, Schleimer K, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2005;37:2185-2187.
170. Guba M, Koehl GE, Neppl E, et al. Dosing of rapamycin is critical to
171. Rapamune (Sirolimus) package insert [Wyeth laboratories Website]. 2006. Available at: http://www.wyeth.com/products?product=/wyeth_html/home/products/ prescription/Rapamunes%20(sirolimus)/Rapamunes%20(sirolimus)_overview.html. Accessed November 13, 2006.
172. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma: after orthotopic liver transplantation: a Pilot Study. Hepatology. 1997;26:444-450.
173. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324-331.
174. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat. 1998;5:29-34.
175. Kulik LM. Can Therapy of hepatitis C affect the development of hepatocellular carcinoma? J Natl Compr Cancer Netw. 2006;4:751-757.
176. Jing X, Zhong-Yang S, Xin-Guo C, et al. A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007;45:269-276.